Search: onr:"swepub:oai:lup.lub.lu.se:9173709b-a038-4e93-8555-a6cd80d4a224" > Glomerular Filtrati...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03885naa a2200409 4500 | |
001 | oai:lup.lub.lu.se:9173709b-a038-4e93-8555-a6cd80d4a224 | |
003 | SwePub | |
008 | 160401s2009 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/15321742 URI |
024 | 7 | a https://doi.org/10.1089/cbr.2009.06282 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Back, Tom4 aut |
245 | 1 0 | a Glomerular Filtration Rate After Alpha-Radioimmunotherapy with At-211-MX35-F(ab ')(2): A Long-Term Study of Renal Function in Nude Mice |
264 | 1 | b Mary Ann Liebert Inc,c 2009 |
520 | a Besides bone marrow, the kidneys are often dose-limiting organs in internal radiotherapy. The effects of high-linear energy transfer (LET) radiation on the kidneys after alpha-radioimmunotherapy (alpha-RIT) with the alpha-particle emitter, At-211, were studied in nude mice by serial measurements of the glomerular filtration rate (GFR). The renal toxicity was evaluated at levels close to the dose limit for the bone marrow and well within the range for therapeutic efficacy on tumors. Astatinated MX35-F(ab ')(2) monoclonal antibodies were administered intravenously to nude mice. Both non-tumor-bearing animals and animals bearing subcutaneous xenografts of the human ovarian cancer cell line, OVCAR-3, were used. The animals received approximately 0.4, 0.8, or 1.2MBq in one, two, or three fractions. The mean absorbed doses to the kidneys ranged from 1.5 to 15 Gy. The renal function was studied by serial GFR measurements, using plasma clearance of Cr-51-EDTA, up to 67 weeks after the first astatine injection. A dose-dependent effect on GFR was found and at the time interval 8-30 weeks after the first administration of astatine, the absorbed doses causing a 50% decrease in GFR were 16.4 +/- 3.3 and 14.0 +/- 4.1 Gy (mean +/- SEM), tumor-and non-tumor-bearing animals, respectively. The reduction in GFR progressed with time, and at the later time interval, (31-67 weeks) the corresponding absorbed doses were 7.5 +/- 2.4 and 11.3 +/- 2.3 Gy, respectively, suggesting that the effects of radiation on the kidneys were manifested late. Examination of the kidney sections showed histologic changes that were overall subdued. Following a-RIT with 211 At-MX35-F(ab')(2) at levels close to the dose limit of severe myelotoxicity, the effects found on renal function were relatively small, with only minor to moderate reductions in GFR. These results suggest that a mean absorbed dose to the kidneys of approximately 10Gy is acceptable, and that the kidneys would not be the primary dose-limiting organ in systemic a-RIT when using At-211-MX35-F(ab')(2). | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a rate | |
653 | a glomerular filtration | |
653 | a renal function | |
653 | a astatine-211 | |
653 | a radioimmunotherapy | |
700 | 1 | a Haraldsson, Boerje4 aut |
700 | 1 | a Hultborn, Ragnar4 aut |
700 | 1 | a Jensen, Holger4 aut |
700 | 1 | a Johansson, Martinu Lund University,Lunds universitet,Patologi, Malmö,Forskargrupper vid Lunds universitet,Pathology, Malmö,Lund University Research Groups4 aut0 (Swepub:lu)med-mim |
700 | 1 | a Lindegren, Sture4 aut |
700 | 1 | a Jacobsson, Lars4 aut |
710 | 2 | a Patologi, Malmöb Forskargrupper vid Lunds universitet4 org |
773 | 0 | t Cancer Biotherapy & Radiopharmaceuticalsd : Mary Ann Liebert Incg 24:6, s. 649-658q 24:6<649-658x 1557-8852x 1084-9785 |
856 | 4 | u http://dx.doi.org/10.1089/cbr.2009.0628y FULLTEXT |
856 | 4 8 | u https://lup.lub.lu.se/record/1532174 |
856 | 4 8 | u https://doi.org/10.1089/cbr.2009.0628 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.